Pathogenesis of Alzheimer disease: Role of oxidative stress, Amyloid-β peptides, systemic ammonia and erythrocyte energy metabolism

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 1, 2014, Pages 112-119

  Kosenko, Elena A ^a,b   Solomadin, Iliya N ^a   Tikhonova, Lyudmila A ^a,b   Prakash Reddy, V ^c   Aliev, Gjumrakch ^d,e   Kaminsky, Yury G ^a  

^a INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

^b PUSHCHINO STATE UNIVERSITY   (Russian Federation)

^c MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (United States)

^d GALLY International Biomedical Research Consulting LLC   (United States)

^e University of Atlanta   (United States)

Author keywords

Alzheimer disease; Ammonia; Amyloid ; Erythrocyte energy metabolism; Oxidative stress

Indexed keywords

6 PHOSPHOFRUCTOKINASE; AMMONIA; AMYLOID BETA PROTEIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LACTATE DEHYDROGENASE; PHOSPHOGLUCONATE DEHYDROGENASE; PHOSPHOGLYCERATE KINASE; PYRUVATE KINASE;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; DOWN SYNDROME; ENERGY METABOLISM; ERYTHROCYTE; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; HUMAN; HYPERAMMONEMIA; HYPOXIA; LIVER FAILURE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REPERFUSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMMONIA; AMYLOID BETA-PEPTIDES; ANIMALS; ENERGY METABOLISM; ERYTHROCYTES; HUMANS; OXIDATIVE STRESS;

EID: 84896714050     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660130     Document Type: Article

References (101)

1. Ferri CP, Prince M, Brayne C, et al. Alzheimer's disease international. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.
2. Teich AF, Arancio O. Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? Biochem J 2012; 446: 165-177.
3. Hebert SS, Horre K, Nicolai L, et al. Loss of microRNA clustermiR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression, Proc Natl Acad Sci USA 2008; 105: 6415-6420.
4. Wang W-X, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of β -site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008; 28: 1213-1223.
5. Perry G, Zhu X, Smith MA, et al. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimer's Dis 2013; 33: S123-S139.
6. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med 2013; 19: 983-997.
7. Bonda DJ, Lee H-P, Kudo W, et al. Pathological implications of cell cycle re-entry in Alzheimer disease. Expert Rev Mol Med 2010; 12: e19/10-e19/11.
8. Kaminsky YG, Marlatt MW, Smith MA, Kosenko EA. Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25-35. Exp Neurol 2010; 221: 26-37.
9. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185.
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
11. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
12. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1131-1135.
13. Arai H, Lee VM, Hill WD, Greenberg BD, Trojanowski JQ. Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease. Brain Res 1992; 585: 386-390.
14. Liberski PP. Amyloid plaques in transmissible spongiform encephalopathies (prion diseases). Folia Neuropathol 2004; 42(Suppl B), 109-119.
15. Jordan BD. Chronic traumatic brain injury associated with boxing. Semin Neurol 1990; 20: 179-185.
16. Roberts GW, Allsop D, Bruton C. The occult aftermath of boxing. J Neurol Neurosurg Psychiatry 1990; 53: 373-378.
17. Omalu BI, DeKosky ST, Minster RL, et al. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 2005; 57: 128-134.
18. Calderón-Garcidueñas L, Solt AC, Henríquez-Roldán C, et al. Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults. Toxicol Pathol 2008; 36: 289-310.
19. Yu NN, Wang XX, Yu JT, et al. Blocking beta2-adrenergic receptor attenuates acute stress-induced amyloid beta peptides production. Brain Res 2010; 1317; 305-310.
20. Perry G, Zhu X, Smith MA, et al. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J Alzheimer's Dis 2013; 33: S111-20.
21. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-866.
22. Nunomura A, Perry G, Hirai K, et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann NY Acad Sci 1999; 893: 362-364.
23. Atwood CS, Robinson SR, Smith MA. Amyloid-beta: redox-metal chelator and antioxidant. J Alzheimers Dis 2002; 4: 203-214.
24. Brewer GJ, Oelshlegel FJ Jr, Moore LG, Noble NA. In vivo red cell glycolytic control and DPG-ATP levels. Ann NY Acad Sci 1974; 241: 513-523.
25. Hoyer S. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta Neurol Scand Suppl 1996; 165: 18-24.
26. Quastel JH. Biochemistry and mental disorder. Lancet 1932; 220: 1417-1419.
27. Hoyer S. Risk factors for Alzheimer's disease during aging. Impacts of glucose/energy metabolism. J Neural Transm Suppl 1998; 54: 187-194.
28. Bruce DG, Davis WA, Casey GP, et al. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle diabetes study. Diabetologia 2009; 52: 1808-1815.
29. Klepper J, Voit T. Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review. Eur J Pediatr 2002; 161: 295-304.
30. Rönnbäck L, Hansson E. On the potential role of glutamate transport in mental fatigue. J Neuroinflammation 2004; 1: 22.
31. Llansola M, Rodrigo R, Monfort P, et al. NMDA receptors in hyperammonemia and hepatic encephalopathy. Metab Brain Dis 2007; 22: 321-335.
32. Auer R, Kalimo H, Olsson Y, Wieloch T. The dentate gyrus in hypoglycemia: pathology implicating excitotoxin-mediated neuronal necrosis. Acta Neuropathol 1985; 67: 279-288.
33. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992; 31: 119-130.
34. +-ATPase. J Neurochem 1994; 63: 2172-2178.
35. Lee HG, Casadesus G, Zhu X, et al. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci 2004; 1019; 1-4.
36. Lee HG, Zhu X, Castellani RJ, et al. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 2007; 321: 823-829.
37. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990; 250: 279-282.
38. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002; 33: 1194-1199.
39. Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010; 5: e9505.
40. Lee HG, Perry G, Zhu X, Nunomura A, Smith MA. Amyloid-β, BACE, and oxidative stress in Alzheimer's disease, a commentary on "The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression". Free Rad Biol Med 2006; 41: 188-189.
41. Smith MA, Atwood CS, Joseph JA, Perry G. Ill-fated amyloid-beta vaccine. J Neurosci Res 2002; 69: 285.
42. Smith MA, Joseph JA, Atwood CS, Perry G. Dangers of the amyloid-beta vaccination. Acta Neuropathol 2002; 104: 110.
43. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54.
44. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452.
45. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med 2010; 220: 95-106.
46. Blass JP. Cerebrometabolic abnormalities in Alzheimer's disease. Neurol Res 2003; 25: 556-566.
47. Hoyer S, Oesterreich K, Wagner O. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol 1988; 235:143-148.
48. Aliev G, Palacios HH, Walrafen B, et al. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int J Biochem Cell Biol 2009; 41: 1989-2004.
49. Aliev G, Li Y, Palacios HH, Obrenovich ME. Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases. Rec Pat Cardiovasc Drug Discov 2011; 6: 222-241.
50. Marcus DL, Freedman ML. Decreased brain glucose metabolism in microvessels from patients with Alzheimer's disease. Ann NY Acad Sci 1997; 826: 248-253.
51. Meier-Ruge W, Iwangoff P, Reichlmeier K. Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Gerontol Geriatr 1984; 3: 161-165.
52. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 2005; 57: 695-703.
53. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 2000; 35: 1363-1372.
54. Kalaria RN, Harik SI. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 1989; 53: 1083-1088.
55. Simpson IA, Davies P. Reduced glucose transporter concentrations in brains of patients with Alzheimer's disease. Ann Neurol 1994; 36: 800-801.
56. de la Torre JC. Alzheimer's disease: how does it start? J Alzheimers Dis 2002; 4: 497-512.
57. de la Torre JC. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann NY Acad Sci 2000; 924: 136-152.
58. Bolaños JP, Almeida A, Moncada S. Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci 2010; 35: 145-149.
59. de la Torre JC, Aliev G. Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes. J Cereb Blood Flow Metab 2005; 25: 663-672.
60. van Wijk R, van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood 2005; 106: 4034-4042.
61. Ajmani RS, Rifkind JM. Hemorheological changes during human aging. Gerontology 1998; 44: 111-120.
62. Mokken FC, Kedaria M, Henny CP, Hardeman MR, Gelb AW. The clinical importance of erythrocyte deformability, a hemorrheological parameter. Ann Hematol 1992; 64: 113-122.
63. Ajmani RS, Metter EJ, Jaykumar R, et al. Hemodynamic changes during aging associated with cerebral blood flow and impaired cognitive function. Neurobiol Aging 2000; 21: 257-269.
64. Sakuta S. Blood filtrability in cerebrovascular disorders, with special reference to erythrocyte deformability and ATP content. Stroke 1981; 12: 824-828.
65. Gov NS, Safran SA. Red blood cell membrane fluctuations and shape controlled by ATP-induced cytoskeletal defects. Biophys J 2005; 88: 1859-1874.
66. Beach TG, Walker R, McGeer EG. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 1989; 2: 420-436.
67. Danon D, Bologna NB, Gavendo S. Memory performance of young and old subjects related to their erythrocyte characteristics. Exp Gerontol 1992; 27: 275-285.
68. Blass JP, Zemcov A. Alzheimer's disease. A metabolic systems degeneration? Neurochem Pathol 1984; 2: 103-114.
69. Giordano V, Peluso G, Iannuccelli M, et al. Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia. Neurochem Res 2007; 32: 555-567.
70. Wen Z, Xie J, Guan Z, et al. A study of hemorheological behaviour for patients with Alzheimer's disease at the early stages. Clin Hemorheol Microcirc 2000; 22: 261-266.
71. Kosenko EA, Aliev G, Tikhonova LA, et al. Antioxidant status and energy state of erythrocytes in Alzheimer dementia: probing for markers. CNS Neurol Disord Drug Targets 2012; 11: 926-932.
72. Kaminsky Y, Poghosyan A, Tikhonova L, et al. Glycolytic and proteolytic metabolism in erythrocytes from elderly and demented patients. Am J Neuroprotect Neuroregener 2012; 4: 73-77.
73. Samaja M, Crespi T, Guazzi M, Vandegriff KD. Oxygen transport in blood at high altitude: role of the hemoglobin-oxygen affinity and impact of the phenomena related to hemoglobin allosterism and red cell function. Eur J Appl Physiol 2003; 90: 351-359.
74. Ponizovsky AM, Barshtein G, Bergelson LD. Biochemical alterations of erythrocytes as an indicator of mental disorders: an overview. Harv Rev Psychiatry 2003; 11: 317-332.
75. Owega A, Klingelhofer J, Sabri O, et al. Cerebral blood flow velocity in acute schizophrenic patients. A transcranial Doppler ultrasonography study. Stroke 1998; 29: 1149-1154.
76. Norberg K, Siesiö BK. Oxidative metabolism of the cerebral cortex of the rat in severe insulin-induced hypoglycaemia. J Neurochem 1976; 26: 345-352.
77. Cooper AJ, Plum F. Biochemistry and physiology of brain ammonia. Physiol Rev 1987; 67: 440-519.
78. Felipo V, Hermenegildo C, Montoliu C, et al. Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention. Neurotoxicology 1998; 19: 675-681.
79. Kosenko E, Montoliu C, Giordano G, et al. Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells. J Neurochem 2004; 89: 1101-1110.
80. Breningstall GN. Neurologic syndromes in hyperammonemic disorders. Pediatr Neurol 1986; 2: 253-262.
81. Monfort P, Cauli O, Montoliu C, et al. Mechanisms of cognitive alterations in hyperammonemia and hepatic encephalopathy: therapeutical implications. Neurochem Int 2009; 55: 106-112.
82. Marchesini G, Bianchi GP, Fabbri A, et al. Synthesis of urea after a protein-rich meal in normal man in relation to ageing. Age Ageing 1990; 19: 4-10.
83. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991; 88: 10540-10543.
84. Hensley K, Hall N, Subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995; 65: 2146-2156.
85. Sims B, Powers RE, Sabina RL, Theibert AB. Elevated adenosine monophosphate deaminase activity in Alzheimer's disease brain. Neurobiol Aging 1998; 19: 385-391.
86. Degrell I, Niklasson F. Purine metabolites in the CSF in presenile and senile dementia of Alzheimer type, and in multi infarct dementia. Arch Gerontol Geriatr 1988; 7: 173-178.
87. Brun A, Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 1981; 5: 549-564.
88. Hawkins RA, Mans AM. Brain metabolism in encephalopathy caused by hyperammonemia. Adv Exp Med Biol 1994; 368: 11-21.
89. Felipo V, Kosenko E, Miñana MD, Marcaida G, Grisolía S. Molecular mechanism of acute ammonia toxicity and of its prevention by L-carnitine. Adv Exp Med Biol 1994; 368: 65-77.
90. Butterworth RF. Molecular neurobiology of acute liver failure. Semin Liver Dis 2003; 23: 251-258.
91. Norenberg MD, Rama Rao KV, Jayakumar AR. Signaling factors in the mechanism of ammonia neurotoxicity. Metab Brain Dis 2009; 24: 103-117.
92. Kosenko E, Felipo V, Montoliu C, et al. Effects of acute hyperammo-nemia in vivo on oxidative metabolism in nonsynaptic rat brain mitochondria. Metab Brain Dis 1997; 12: 69-82.
93. Kosenko E, Kaminsky Y, Solomadin I, et al. Acute ammonia neurotoxicity in vivo involves increase in cytoplasmic protein P53 without alterations in other markers of apoptosis. J Neurosci Res 2007; 85: 2491-2499.
94. Kosenko E, Kaminski Y, Lopata O, Muravyov N, Felipo V. Blocking NMDA Receptors Prevents the oxidative stress induced by acute ammonia intoxication. Free Radic Biol Med 1999; 26: 1369-1374.
95. Kosenko E, Kaminsky Y, Kaminsky A, et al. Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic Res 1997; 27: 637-644.
96. Kosenko E, Venediktova N, Kaminsky Y, et al. Sources of oxygen radicals in brain in acute ammonia intoxication in vivo. Brain Res 2003; 981: 193-200.
97. Moreira PI, Nunomura A, Nakamura M, et al. Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med 2008; 44: 1493-1505.
98. Kosenko E, Kaminsky Y, Lopata O, et al. Nitroarginine, an inhibitor of nitric oxide synthase, prevents changes in superoxide radical and antioxidant enzymes induced by ammonia intoxication. Metab Brain Dis 1998; 13: 29-41.
99. Kosenko E, Kaminsky Y, Stavroskaya IG, Felipo V. Alteration of mitochondrial calcium homeostasis by ammonia-induced activation of NMDA receptors in rat brain in vivo. Brain Res 2000; 880: 139-146.
100. Smith MA, Richey Harris PL, et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997; 17: 2653-2657.
101. Kaminsky GY, Reddy VP, Ashraf GMD, et al. Age-related defects in erythrocyte 2:3-diphosphoglycerate metabolism in dementia. Aging Disease, 2013; 4: 2442-2455.